HT. Activation of ␣ 1B-adrenoceptors contributes to intermittent hypobaric hypoxia-improved postischemic myocardial performance via inhibiting MMP-2 activation. Am J Physiol Heart Circ Physiol 306: H1569 -H1581, 2014. First published April 4, 2014; doi:10.1152/ajpheart.00772.2013.-Inhibition of matrix metalloproteinases-2 (MMP-2) activation renders cardioprotection from ischemia/reperfusion (I/R) injury; however, the signaling pathways involved have not been fully understood. Intermittent hypobaric hypoxia (IHH) has been shown to enhance myocardial tolerance to I/R injury via triggering intrinsic adaptive responses. Here we investigated whether IHH protects the heart against I/R injury via the regulation of MMP-2 and how the MMP-2 is regulated. IHH (PO 2 ϭ 84 mmHg, 4-h/day, 4 wk) improved postischemic myocardial contractile performance, lactate dehydrogenase (LDH) release, and infarct size in isolated perfused rat hearts. Moreover, IHH reversed I/R-induced MMP-2 activation and release, disorders in the levels of MMP-2 regulators, peroxynitrite (ONOO Ϫ ) and tissue inhibitor of metalloproteinase-4 (TIMP-4), and loss of the MMP-2 targets ␣-actinin and troponin I. This protection was mimicked, but not augmented, by a MMP inhibitor doxycycline and lost by the ␣1-adrenoceptor (AR) antagonist prazosin. Furthermore, IHH increased myocardial ␣1A-AR and ␣1B-AR density but not ␣1D-AR after I/R. Concomitantly, IHH further enhanced the translocation of PKC epsilon (PKCε) and decreased the release of mitochondrial cytochrome c due to I/R via the activation of ␣1B-AR but not ␣1A-AR or ␣1D-AR. IHH-conferred cardioprotection in the postischemic contractile function, LDH release, MMP-2 activation, and nitrotyrosine as well as TIMP-4 contents were mimicked but not additive by ␣1-AR stimulation with phenylephrine and were abolished by an ␣1B-AR antagonist chloroethylclonidine and a PKCε inhibitor PKCε V1-2. These findings demonstrate that IHH exerts cardioprotection through attenuating excess ONOO Ϫ biosynthesis and TIMP-4 loss and sequential MMP-2 activation via the activation of ␣1B-AR/PKCε pathway.
ischemia/reperfusion (I/R) injury via the proteolysis of specific protein targets within the cardiomyocytes, whereas the inhibition of MMP-2 improves the postischemic recovery of myocardial contractile function (1, 10, 29) . MMP-2 activity is tightly controlled by endogenous inhibitors, such as tissue inhibitors of metalloproteinase (TIMPs), especially TIMP-4, in the heart with or without I/R (29, 33, 44) . Meanwhile, MMP-2 is directly activated by peroxynitrite (ONOO Ϫ ), the reaction product of nitric oxide (NO) and superoxide (O 2 ·Ϫ ), which is overgenerated upon first reperfusion following ischemia (29, 48, 53) . Ischemic preconditioning (IPC) or other conditioning forms significantly resist the I/R-induced ONOO Ϫ overproduction or TIMP-4 loss and thus exert myocardial protection via sequentially diminishing the activation of MMP-2 (8, 15, 31, 45) . However, the signaling pathway regulating the ONOO Ϫ and TIMP-4 during cardioprotection has not yet been fully clarified.
␣ 1 -Adrenoceptor (␣ 1 -AR) activation has been shown to mimic IPC and trigger intrinsic adaptive responses to protect the heart against subsequent I/R-induced myocardial dysfunction and infarction (5, 18, 37, 49, 52) . We previously demonstrated that ␣ 1 -AR stimulation with phenylephrine alleviates I/R injury via protecting the mitochondrial function through the ␣ 1B -AR-activated PKC epsilon (PKCε)-mediated mitochondria ATP-sensitive potassium (mito-K ATP ) channel opening in rat cardiomyocytes (18) , while it is unknown whether the activation of ␣ 1 -ARs regulates MMP-2 in the cardioprotection against I/R injury.
Myocardial tolerance to ischemia has also been observed in people living at a high altitude (Peru, 4,000 m) (27) and in experimental animals using a simulated model of chronic intermittent hypobaric hypoxia (IHH) to mimic the physiological adaptation to altitude in the laboratory (3, 9, 34, 38, 58, 59, 61, 62, 68) . This form of cardioprotection is reproducible in improving postischemic recovery of contractile function, reducing the incidence and severity of arrhythmias, and limiting the infract size (3, 9, 34, 38, 58, 61, 62, 68) , and it has the merits of maintaining the cardioprotection longer than classic IPC and having less adverse effects such as right ventricular hypertrophy compared with the chronic continuous hypoxia (3, 58, 59, 69) . Therefore, IHH provides us a unique model to better understand how the intrinsic defense system is triggered and developed. We found that IHH has a better improvement in the I/R-suppressed cell contraction than in the Ca 2ϩ transients (9) , an indication of the preservation of myofilament during I/R by IHH. Moreover, cardiac sympathetic stimulation and ␣ 1 -AR activation have been shown to play an important role in the cardioprotective effect of IHH (35, 56) , while it is unclear whether IHH exerts cardioprotection against MMP-2 activation via ␣ 1 -ARs. Considering a critical role of MMP-2 in the proteolysis of myofilament, such as troponin I (TnI) and ␣-actinin (2, 4, 47, 54) , we hypothesized that the inhibiting of MMP-2 activation might contribute to the chronic IHH-conferred cardioprotection against I/R injury through the activation of ␣ 1 -AR.
To address those questions, the present study was designed 1) to determine whether IHH protects the heart via the regulation of MMP-2 activation; 2) to clarify whether ␣ 1 -ARs regulate MMP-2 and its regulators during cardioprotection against I/R injury; and 3) to identify the signaling pathway implicated in the regulation of MMP-2 during cardioprotection.
MATERIALS AND METHODS
Animal care. The animals used in this study were maintained in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Pub. No. , and all procedures were approved by the Institutional Review Board of the Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and School of Medicine, Shanghai Jiao Tong University (Shanghai, China).
IHH adapted rat model. To establish animal models adapted to IHH, male Sprague-Dawley rats were exposed to hypoxia in a hypobaric chamber (equivalent to an altitude of 5,000 m; barometric pressure ϭ 404 mmHg, PO 2 ϭ 84 mmHg) for one 4-h period each day for 4 wk as previously described (58) . During this period, their body weight rose from 100 -130 g to 310 -360 g. Age-matched normoxic animals were maintained in the normoxic environment for a corresponding period. All animals had free access to water and a standard laboratory diet and were raised at room temperature (23-26°C) with a 12-h light-dark cycle. Body weights of rats were measured weekly.
Heart perfusion. The rats were anesthetized with sodium pentobarbital (45 mg/kg ip). The hearts were promptly excised and perfused with Krebs-Henseleit buffer containing the following (in mM): 118 NaCl, 4.7 KCl, 1.2 MgSO 4·7H2O, 2.5 CaCl2, 1.2 KH2PO4, 25 NaHCO 3, 0.026 Na2-EDTA, and 11.1 glucose, gassed with 95% O 2-5% CO2 (pH 7.4) at 37°C by using the Langendorff technique under a constant pressure of 80 mmHg as previously described (58, 66) . Left ventricle (LV) developed pressure (LVDP), LV end-diastolic pressure (LVEDP), maximal rate of pressure development (ϩdP/ dt max), and decay over time (ϪdP/dtmax), heart rate and rate-pressure product (RPP) were synchronously monitored with PowerLab system (AD Instrument, New South Wales, Australia).
Experimental protocols for isolated rat hearts. After equilibration perfusion, the hearts from normoxic or IHH rats were subjected to 30 min no-flow global ischemia followed by 30 or 120 min of reperfusion. The MMP inhibitor doxycycline (100 M) (10) and the ␣ 1-AR antagonist prazosin (1 M) (25, 55, 56) were perfused for 10 min before ischemia, and for the first 10 min of reperfusion, and the ␣ 1-AR agonist phenylephrine (10 M) (5, 18, 40, 42, 52) was perfused for 5 min followed a 10-min washout before ischemia. The antagonists 5-methylurapidil (5-MU; 1 M) (18, 21, 22, 65, 67) for ␣ 1A-AR and BMY7378 (1 M) (18, 67) for ␣ 1D-AR were perfused for 10 min before ischemia and maintained during the reperfusion period, and the ␣ 1B-AR antagonist chloroethylclonidine (CEC; 10 M) (18, 63) was perfused for 15 min before ischemia. The above reagents were from Sigma (St. Louis, MO). Myristoylated PKCε V1-2 (a PKCε-specific inhibitor; 10 M; Biomol, Hamburg, Germany) (18, 23, 28, 58) was perfused for 5 min followed a 5-min washout before ischemia. All above reagents were dissolved in the deionized distilled water and added to perfusate at corresponding concentrations. At the end of the experiments, the hearts were freeze clamped and stored at Ϫ80°C. Coronary effluents were collected at 1 min before ischemia and at 3 and 30 min of reperfusion and stored at Ϫ80°C.
Measurement of LDH. LDH was spectrophotometrically measured in the coronary effluent at preischemia and at 3 and 30 min of reperfusion using a LDH assay kit (Jianchen Bioengineering Institute, Nanjing, China) as previously described (58, 66) .
Infarct size estimation. The hearts subjected to I/R (30 min/120 min) were frozen and cut into 2-mm-thick slices as previously described (15, 58) . Sections were then incubated in 1% triphenyltetrazolium chloride for staining. The infarct size was measured by planimetry (Image Pro Plus, Media Cybernetics, MD) and represented as a percentage of the LV area at risk.
Measurement of the activity of MMP-2 in coronary effluent. The activity of MMP-2 in coronary effluent was determined by the fluorescent method as previously described (11) using GenMed MMP-2 Fluorimetric Assay Kit (GenMed Scientifics, Shanghai, China) according to the manufacturer's instruction. Briefly, the collected coronary effluent samples were concentrated in Amicon Ultra Centrifugal 4 ml-10 K concentrating vessels (4,000 g, 4°C; Millipore). Then, proteins of concentrated samples were measured by the BCA method and balanced to an equal protein concentration by adding Krebs-Henseleit buffer. Twenty-microliter balanced samples (5 g total proteins) were added to an 80-l reaction mixture containing MMP fluorescence resonance energy transfer (FRET) peptide substrate [Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH 2, where Mca is (7-methoxy-coumarin-4-yl) acetyl and Dpa is
The fluorescence intensity was measured at 2-min intervals for 1 h at 37°C using a SPECTRAmax Gemini XPS fluorescence microplate reader (ex: 328 nm; em: 393 nm; Molecular Devices). The specific activity of MMP-2/g protein in the coronary effluent was calculated as the OA-Hy-nonsensitive activity subtracted from the total activity. One unit of MMP-2 activity was defined as the amount of OA-Hy-sensitive enzyme that hydrolyzes 1 nM of peptide substrate per min at 37°C (pH 7.5).
Western blotting. The total protein fraction was prepared as described previously (58) . Briefly, LV tissues were homogenized in lysis buffer containing the following (in mM): 20 Tris, 150 NaCl, 2.5 EDTA, 50 NaF, 0.1 Na4P2O7, 1 Na3VO4, 1 PMSF, 1 DTT, 1 g/ml leupeptin, and 1% Triton X-100 (pH 7.4, 4°C) using a Polytron PT 3100 homogenizer (Kinematica, Littau-Lucerne, Switzerland). The homogenate was kept on ice for 30 min and then centrifuged at 10,000 g for 20 min at 4°C, and the supernatant was saved as total protein fraction. For examining PKCε translocation, the membrane and cytosol fractions were separated as previously described (58) . LV tissues were homogenized in lysis buffer containing the following (in mM): 20 Tris·HCl (pH 7.4), 250 sucrose, 1 EDTA, 1 EGTA, 1 NaF, 1 Na3VO4, 1 PMSF, and 1 DTT with 0.2% (vol/vol) protease inhibitor cocktail and centrifuged at 1,000 g for 10 min at 4°C. The supernatant was centrifuged at 10,000 g for 30 min at 4°C, and the pellet was washed once with lysis buffer by centrifugation, resuspended with 0.5% Triton X-100 in lysis buffer, sonicated on ice, and then centrifuged at 20,000 g for 10 min at 4°C. The resultant supernatant was defined as the membrane fraction. The supernatant after the membrane fraction had been pelleted and was centrifuged at 100,000 g for 1 h at 4°C, and the resultant supernatant was defined as the cytosolic fraction. Triton X-100 was added at a final concentration of 0.5%. For analysis of cytochrome c release, the mitochondrial and cytoplasmic compartments were fractionated as previously described (18) . Briefly, frozen LV tissues were homogenized in lysis buffer containing the following (in mM): 20 HEPES (pH 7.5), 10 KCl, 1.5 MgCl2, 1 EDTA, 1 EGTA, 1 DTT, 0.1 PMSF, 1 leupeptin, and 250 sucrose. The homogenate was centrifuged at 750 g at 4°C. The supernatant was aspirated and centrifuged at 10,000 g at 4°C. The pellet containing the mitochondrial fraction was resuspended in lysis buffer. The superna-tant was centrifuged at 100,000 g at 4°C to remove any mitochondrial contamination and saved as cytoplasmic compartments. The protein concentrations were determined by BCA method. The specific protein marker and contamination control for each fractions were assayed by immunoblotting.
The standard Western blot was performed as previously described (58) . Equal protein fractions were separated by electrophoresis on SDS-PAGE gels. After being transferred to PVDF, proteins were probed with primary specific antibodies [anti-MMP-2, 72 kDa, 1:500, Chemicon, CA; anti-TnI, anti-voltage-dependent anion-selective channel proteins-1 (VDAC-1) and anti-cytochrome c, 1:1,000, Santa Cruz, TX; anti-␣-actinin and anti-PKCε, 1:1,000, Sigma; anti-Na ϩ / Ca 2ϩ exchanger-1 (NCX-1), 1:1,000, Abcam, Cambridge, UK; and GAPDH, 1:10,000; KangChen, Shanghai, China] overnight at 4°C. The immunoreaction was visualized using an enhanced chemiluminescent detection kit (Amersham, London, UK), exposed to X-ray film, and quantified by densitometry with a video documentation system (Gel Doc 2000; Bio-Rad, Hercules, CA).
RT-PCR. Total RNA was extracted from LV tissue with Trizol Reagent (Invitrogen, Carlsbad, CA). cDNA was prepared by reverse transcription of 1 g total RNA using the oligo (dT) primer and ReverTra Ace reverse transcriptase (Toyobo, Osaka, Japan). PCR was D C A Normoxia+doxycycline (7) Normoxia ( carried out for 30 cycles using Taq DNA Polymerase (Takara, Shiga, Japan) as previously described (6) . The following primers were used: MMP-2 sense, 5=-CCCCTATCTACACCTACACCAAGAAC-3=; MMP-2 antisense, 5=-CATTCCAGGAGTCTGCGATGAGC-3=; GAPDH sense, 5=-ACGACCCCTTCATTGACC-3=; and GAPDH antisense, 5=-TGCTTCACCACCTTCTTG-3=. Cardiac nitrotyrosine measurement. As a marker of the cardiac ONOO Ϫ formation, the nitrotyrosine level of LV tissue extracts at 30 min of reperfusion was measured using an enzyme-linked immunosorbent assay (Cell Biolabs) as previously described (20, 50) . Nitrotyrosine content was normalized to protein content of myocardium extracts and expressed as picogram per milligram of protein.
Radioligand binding assay. The preparation of crude LV membrane fraction and radioligand binding assay were performed as described previously (67) . The ␣ 1-AR antagonist 2-b(4-hydroxyphenyl)-ethylaminomethyl-tetralone (BE2254; Beiersdorf, Hamburg, Germany) was radioiodinated with 125 I-Na ϩ (Beijing Institute of Atomic Energy, Beijing, China) using the chloramine T method. Then, the membrane preparation (1 mg/ml) was incubated with 125 I-BE2254 (2,200 Ci/mM) for 20 min at 37°C in the presence or absence of competing drugs, and the incubation was terminated by 10 mM Tris·HCl. The mixture was filtered, washed, dried, and measured for its radioactivity and protein concentration. Nonspecific binding was determined in the presence of 10 M of phentolamine (Sigma). To determine the affinity (K D) and the maximal binding capacity (Bmax) of 125 I-BE2254 to cardiac ␣1-ARs, saturation curves were determined by incubating membrane preparations with increasing concentrations of 125 I-BE2254 (35-640 pM, 2.8 -52.1 MBq) and the data were analyzed by the method of Scatchard. About 50 pM 125 I-BE2254 (4 MBq) was incubated with 100-l membrane preparations in the presence of 16 concentrations of 5-MU and BMY7378 to gain the competitive binding curve. The B max of ␣1A-and ␣1D-subtypes were calculated from the percentage of high affinity site of the 5-MU and BMY7378 using Prism software, and the rest of the total B max was evaluated as of ␣ 1B-AR subtype.
Statistic analysis. Data are presented as means Ϯ SE. Statistical significance was determined using ANOVA or repeated ANOVA for multiple comparisons or repeated measurements. P Ͻ 0.05 was regarded as statistically significant.
RESULTS

IHH improves the postischemic recovery of myocardial performance and cell survival via inhibiting MMP-2 activation.
To determine whether IHH protects the heart against I/R injury via the regulation of MMPs, we first examined hemodynamic changes during I/R in Langendorff-perfused rat hearts with or without a MMP inhibitor doxycycline (10) LVEDP, ϮdP/dt max , and RPP, was suppressed by I/R (30 min/30 min), although the heart rate remained unchanged (Fig. 1) . These suppressions were significantly improved by IHH, while the preischemic values and heart rate were comparable between the two groups (Fig. 1) . Consistently, IHH significantly attenuated I/R-induced increases of LDH release in coronary perfusate (an indicator of cell damage) at 3 and 30 min of reperfusion and LVDP and RPP suppression and myocardial infarct size after 2 h of reperfusion without affecting the heart rate ( Fig. 2) . Doxycycline (100 M) mimicked the cardioprotective effects of IHH on the postischemic myocardial performance, LDH release, and infarct size, but it had no additive protective effects to the IHH and did not affect the preischemic values and heart rate during I/R (Figs. 1 and 2) . Besides, the weight gain of normoxic and IHH rats was comparable (IHH: from 120.5 Ϯ 1.4 to 323.5 Ϯ 2.4 g vs. normoxia: from 120.9 Ϯ 1.3 to 325.3 Ϯ 2.6 g, n ϭ 30 each) as observed previously (58) . Because MMP-2 has been shown to play an important role in early myocardial I/R injury (29), we next analyzed whether IHH affects the MMP-2 activity and expression during I/R. The MMP-2 activity in coronary effluent was significantly increased at 3 min of reperfusion in the normoxic control group (Fig. 3A) . Concomitantly, the protein content of 72-kDa MMP-2 in LV tissue from normoxic group was decreased (Fig.  3B ) because of its activation and release from myocytes during reperfusion for the purpose of cell self-rescue (10), while the mRNA level of MMP-2 remained unchanged after I/R (Fig.  3C) . In contrast, IHH attenuated I/R-induced MMP-2 activation and release and preserved the myocardial MMP-2 protein content during reperfusion without affection the MMP-2 mRNA level (Fig. 3, A-C) . Moreover, ␣-actinin and TnI, two sensitive proteolysis substrates of MMP-2 (47, 54), were decreased after I/R. The lower molecular mass fragment of TnI (ϳ22 kDa) after I/R was also detected (Fig. 3D) . These changes were reversed by IHH or doxycycline, but both of them had no additive protective effects (Fig. 3, A, B, and D) , indicating that the cardioprotection of IHH is mediated through the inhibition of MMP-2 activation during I/R.
IHH inhibits MMP-2 activation via reversing I/R-induced ONOO
Ϫ overgeneration and TIMP-4 loss. ONOO Ϫ overgeneration and TIMP-4 loss have been reported to undertake the responsibility for the activation of MMP-2 (29, 44, 53) . We thus examined the effects of IHH on the alternations of ONOO Ϫ formation and TIMP-4 level due to I/R. I/R induced a marked increase of nitrotyrosine content (Fig. 4A) , reflecting the ONOO Ϫ formation (50), and a decrease of TIMP-4 protein level in the LV (Fig. 4B ), while these disorders were significantly attenuated by IHH (Fig. 4) . Thus IHH reduced MMP-2 activation against I/R injury through the inhibition of overgeneration of ONOO Ϫ and loss of TIMP-4. ␣ 1B -AR mediates the IHH-conferred cardioprotection on the contractile function, cell survival, and MMP-2 activation. Because the activation of ␣ 1 -ARs mimics IPC against I/R injury by activating endogenous adaptive responses and contributes to IHH-afforded cardioprotection (5, 18, 37, 52, 56), we then investigated a potential involvement of ␣ 1 -ARs in the IHH-regulated MMP-2 activation. The ␣ 1 -ARs antagonist prazosin at 1 M abolished IHH-conferred improvement of postischemic myocardial performance, LDH release, and myocardial infarction, but it did not affect I/R-induced disorders ( Figs.   1 and 2) . Consistently, IHH-attenuated I/R-induced the activation and release of MMP-2, reduction of ␣-actinin and TnI protein contents, increase of nitrotyrosine content, and decrease of TIMP-4 protein content were also abolished by prazosin ( Fig. 3 and 4) .
To determine if there were changes in the ␣ 1 -AR subtype, we then performed competition ligand binding experiment as reported previously (67) . The total density and affinity of ␣ 1 -ARs at preischemia were comparable between the LV from normoxic and IHH rats, while IHH not only reversed I/Rdecreased density of ␣ 1 -ARs but also enhanced it further at 30 min of reperfusion, although it did not alter the affinity of ␣ 1 -ARs before or after I/R (Fig. 5, A and B) . The densities of ␣ 1A -AR and ␣ 1D -AR at 30 min of reperfusion were lower than the values at preischemia, whereas the density of ␣ 1B -AR remained unchanged (Fig. 5C ). However, IHH significantly increased the densities of ␣ 1A -AR and ␣ 1B -AR at both preischemia and reperfusion, but it decreased the density of ␣ 1D -AR only at preischemia (Fig. 5C) . Therefore, IHH changed the † ratio of three ␣ 1 -AR subtypes by increases of ␣ 1A -and ␣ 1B -AR ratios but the decrease of ␣ 1D -AR ratio in LV myocardium before and after I/R. Next, the contribution of three ␣ 1 -AR subtypes to the IHHafforded cardioprotection was investigated by the ␣ 1 -AR stimulation with 10 M of phenylephrine or by the specific inhibition of ␣ 1A -, ␣ 1B -, or ␣ 1D -AR subtype with the antagonist 5-MU (1 M), CEC (10 M), or BMY7378 (1 M), respectively. The cardioprotective effects of IHH on the postischemic myocardial performance, LDH release, activation and release of MMP-2 (Fig. 6) , as well as nitrotyrosine and TIMP-4 protein contents (Fig. 7) were mimicked but not augmented by phenylephrine, while they were totally inhibited by the ␣ 1B -AR antagonist CEC but not the ␣ 1A -or ␣ 1D -AR antagonist 5-MU or BMY7378 (Figs. 6 and 7) . These results reveal a crucial role of ␣ 1B -AR in the cardioprotection of IHH against I/R-induced overgeneration of ONOO Ϫ , loss of TIMP-4 protein, and the subsequent activation of MMP-2, as well as resultant myocardial performance and cell survival.
TIMP-4 GAPDH
IHH-conferred cardioprotection on the contractile function, cell survival, and MMP-2 activation through ␣ 1B -AR-mediated PKC activation and subsequent mitochondrial protection.
We previously demonstrated that stimulation of ␣ 1B -AR activates PKCε, resulting in the cardioprotection on the mitochondrial function (18) . To further determine whether ␣ 1B -AR-mediated PKCε pathway is involved in the IHH-conferred cardioprotection on the regulation of MMP-2, we analyzed the effect of PKCε-specific inhibitor PKCε V1-2 on the cardioprotection of IHH, the translocation of PKCε (an indirect index of PKCε activation), and mitochondrial cytochrome c release (a marker of mitochondrial damage) (18, 58) . PKCε V1-2 (10 M) did not affect the corresponding normoxic values, but it totally reversed the IHH-improved postischemic myocardial contractile function, inhibited LDH release and MMP-2 activation and release (Fig. 6) , and attenuated nitrotyrosine content and TIMP-4 loss (Fig. 7) . In addition, IHH further enhanced I/R-promoted translocation of PKCε from cytosol to membrane and decreased I/R-induced release of cytochrome c from mitochondria without affecting the preischemic values (Fig. 8) . The effects of IHH were mimicked but not further augmented by phenylephrine, while it was inhibited by CEC rather than 5-MU or BMY7378 (Fig. 8) . Further, IHH-decreased mitochondrial cytochrome c release due to I/R was reversed by PKCε V1-2 (Fig. 8B) . No significant contamination between the membrane and cytosolic fraction was observed as NCX-1 (membrane marker) and GAPDH (cytosolic marker) were only detected in the membrane and cytosolic fractions, respectively (Fig. 8A, top) . Similarly, no significant contamination between the mitochondrial and cytosolic fractions was observed as VDAC-1 (mitochondrial marker) and GAPDH (cytosolic marker) were only detected in the mitochondrial and cytosolic fractions, respectively (Fig. 8B, top) . These results indicate that the ␣ 1B -AR plays an important role in the IHH-conferred cardioprotection via the regulation of MMP-2 activation through the activation of PKCε and the protection of the mitochondria integrity under I/R insult.
DISCUSSION
In this study, we confirmed the cardioprotection of IHH on the improvement of the postischemic myocardial performance and cell survival and revealed the new mechanisms responsible for its cardioprotective effects. The main findings are 1) IHH improves the postischemic myocardial performance and cell survival via inhibiting I/R-induced activation and release of MMP-2 and subsequently reduce the decrease of ␣-actinin and TnI; 2) the inhibitory effect of IHH on the MMP-2 activation is dependent on the reversal of I/R-induced ONOO Ϫ overgeneration and TIMP-4 loss; and 3) IHH inhibits MMP-2 activation and release through the attenuation of I/R-induced ONOO Ϫ overgeneration and TIMP-4 loss via ␣ 1B -AR and subsequently activated PKCε pathway. A schematic representation for the IHH-stimulated protective pathway in the regulation of MMP-2 activation during I/R is shown in Fig. 9 . These findings extend previous knowledge and provide a new insight into the importance of ␣ 1B -AR/PKCε pathway on the regulation of MMP-2 activation in the cardioprotection against I/R injury.
Inhibiting MMP-2 activation plays a crucial role in the cardioprotection afforded by IHH. Cumulated evidence shows that MMP-2 is involved in the acute myocardial I/R injury (1, 10, 29, 54) . MMP-2 widely locates in the sarcomere, cytosol, mitochondrion, nucleus, and other organelles of cardiomyocyte (12, 26, 29) . Upon first reperfusion, MMP-2 is largely activated and cleaves a series of proteins, such as TnI, myosin light chain-1 (MLC-1), and titin, resulting in severe contractile dysfunction and cell death (1, 29, 47, 54) , while the MMP-2 inhibition decreases the intracellular protein degradation, improves the recovery of myocardial contractile dysfunction, and reduces infarct size in I/R hearts (10, 13, 17) . Therefore, inhibiting the activation of MMP-2 appears to be a common downstream mediator in various forms of cardioprotectiontriggered intrinsic adaptive responses, such as IPC, postischemia conditioning, noninvasive limb IPC, and pharmacological conditioning (rosuvastatin and high-density lipoproteins) (6, 13, 15, 31, 32) . This view is supported by our findings here by using of the chronic IHH adaptive model. Since the first report for the cardiac beneficial effects of altitude anoxia in 1958 (30), more and more evidence has shown that intermittent hypoxia, characterized by repeated episodes of hypoxia/reoxygenation, has profound effects on the susceptibility of the myocardium to I/R injury (3, 34, 58, 61, 62, 68) . Moreover, IHH improves myocardial perfusion in patients with severe coronary heart diseases (14) and has a therapeutic effect on the permanent coronary artery ligationinduced animal myocardial infarction by attenuating infarct size and myocardial fibrosis and improving cardiac performance (61) . Therefore, IHH may offer beneficial effects to patients with acute myocardial infarction if the mechanistic insights underlying the cardioprotective effects of IHH are achieved (14, 39) . We previously showed that the activation of protein kinase A during the end of ischemia and early reperfusion, phosphoinositide 3-kinase/protein kinase B (PI3K/ Akt), calcium/calmodulin-dependent protein kinase II, reactive oxygen species during the reperfusion, the preservation of Ca 2ϩ handing proteins abundance/activity at sarcolamma and sarcoplasmic reticulum, and the mitochondrial structure and function contribute to the IHH-conferred cardioprotection (9, 58, 60, 62) . These findings together with the observation of the regulation of MMP-2 activation by IHH here suggest that the protective mechanisms in IHH are similar as the classic IPC (64) , but the chronic IHH has more significant regulations in the levels of protein expressions (57) .
IHH inhibits MMP-2 activation during I/R through regulating ONOO
Ϫ generation and TIMP-4 loss. MMP-2 is tightly regulated at several levels including transcriptional, posttranscriptional, and posttranslational levels (29) , although the specific regulation under various physiological and pathophysio- logical conditions have not yet been fully clarified. Chronic hypoxia (48 h) was reported to inhibit MMP-2 activation, but it does not affect the MMP-2 protein expression in human cardiac myofibroblasts (41) . Similarly, chronic IHH alone does not alter LV MMP-2 protein level (46) . This is supported by our data here showing that the chronic IHH does not alter the preischemic MMP-2 mRNA and protein level but reduces the postischemic MMP-2 activation in LV. MMP-2 is synthesized as a proenzyme and can be activated by proteolytic cleavage of its inhibitory pro-peptide domain (29) . A large body of experimental evidence supports that the early reperfusion leads to an increase in oxidative stress when oxygen is reintroduced to ischemic tissue. Therefore, simultaneous production of NO and O 2 ·Ϫ will react to generate ONOO Ϫ , which activates the endogenic MMP-2 by oxidizing the sulphydryl bond between a cysteine residue of the prodomain and the Zn 2ϩ catalytic center and produces myocardial dysfunction (29, 53) . Endogenous inhibitors, such as TIMPs, tightly control MMP-2 activity. Four TIMPs have been identified to date, of which TIMP-4 is expressed predominantly in the heart compared with others (29, 44) . I/R injury-induced rapid loss of myocardial TIMP-4 also results in an increase of net myocardial MMP-2 activity (33, 44) . Moreover, the overgeneration of ONOO Ϫ inhibits TIMP-4 activity, which turns to indirectly activate MMP-2 (16). Interestingly, we found here that the IHH can reverse I/R-induced activation of MMP-2 The ␣ 1B -AR/PKC pathway plays an important role in the regulation of MMP-2 activation. The PI3K/Akt and JAK2-ERK pathways have been shown to be involved in the modulation of MMP-2 activation under cardioprotection against I/R injury (8, 45) . Here we showed another signaling pathway mediated by ␣ 1B -AR/PKCε being involved in the regulation of MMP-2 activation in the cardioprotection against I/R injury. It has been well documented that ␣ 1 -AR activation induces the cardioprotection against I/R injury in animal experiments (5, 18, 37, 52) , while the role of ␣ 1 -AR subtypes (␣ 1A -AR, ␣ 1B -AR, and ␣ 1D -AR) in the cardioprotection remains controversial (18, 19, 25, 43) . IHH has been shown to increase the activity of ␣ 1 -ARs and thus improve the contraction of papillary muscle during simulated ischemia (56) . Our data here further reveal that IHH exerts cardioprotection via the increases of postischemic ␣ 1B -AR density and activity and the subsequent activation of PKCε but not other ␣ 1 -AR subtypes in rat hearts. This is consistent with the reports from other and our laboratories showing that the activation of ␣ 1B -AR/PKC pathway plays an important role in the IPC and ␣ 1 -AR stimulationconferred cardioprotection (18, 25) . Consistent with our results of the increase in ␣ 1 -AR density by the chronic IHH, an 8-wk treatment of testosterone has been shown to confer cardioprotection against I/R injury by upregulating the cardiac ␣ 1 -AR and enhancing the effects of ␣ 1 -AR stimulation (51) . However, we could not find reports related to the increase of ␣ 1B -AR density in classic IPC. Therefore, the activation of ␣ 1B -AR/ PKCε pathway appears to be a common mechanism in cardioprotection, while the increase of ␣ 1B -AR density seems to be mainly involved in the chronic conditioning. This mechanism may help the cell to deal with the stress more effectively and needs to be further investigated for the correlation between the extent and duration of IHH with the magnitude of increases in the ␣ 1B -AR density.
PKCε is a most abundant novel PKC isozyme found in adult rat cardiac myocytes and plays an essential role in the development of cardioprotection (18, 24, 58) . Its activation, accompanying with the translocation from cytosolic to particulate compartments, has been showed to arouse the intrinsic cardioprotective mechanisms, such as opening mitochondrial ATPsensitive potassium (mitoK ATP ) channels and maintaining mitochondrial integrity and function against I/R injury (18, 24, 58) . The protection on mitochondria attenuates oxidative stress and sequential O 2 ·Ϫ and ONOO Ϫ overgeneration (7, 48) . Moreover, mitochondria protection-mediated decreases of oxidative stress and intracellular Ca 2ϩ overloading alter the activities of proteases and reduce intracellular protein lysis and release (18, 24, 36) . Because IHH inhibits the opening of mitochondrial permeability transition pores and opens mitoK ATP channels to enhance the mitochondria tolerance to reperfusion injury (3, 38, 59, 68) , the mitochondrial protection mediated by the IHH-stimulated ␣ 1B -AR/PKCε pathway may subsequently attenuate O 2 ·Ϫ and sequential ONOO Ϫ overgeneration and inhibit protease activation and sequential TIMP-4 loss to reduce MMP-2 activation against I/R injury.
One limitation of the present study is that all of the data were collected from the use of inhibitors or activator. To exclude potential nonspecific and side effects of those reagents, genetic manipulation of ␣ 1 -AR subtypes by overexpression or specific knockdown in the hearts from normoxic and IHH-adapted rats needs to be carried out to further confirm those findings.
In conclusion, our results demonstrate that IHH improves the postischemic recovery of myocardial dysfunction and cell death via the suppressing of I/R-induced overgeneration of ONOO Ϫ and loss of TIMP-4 through the activation of the ␣ 1B -AR/PKCε pathway and the subsequent inhibition of MMP-2 activation.
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